We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Using Mass Photometry To Power Up the Development of AAV-Based Therapeutic  featuring Dr. Matt Ranaghan

Enhancing the Development of AAV-Based Therapeutics With Mass Photometry

Adeno-associated vectors (AAVs) are transforming therapeutics – from gene therapy to vaccines.

A major challenge when developing AAV-based therapeutics is ensuring that empty AAVs that lack therapeutic DNA are removed, increasing the efficacy of the product.

But the empty AAVs are chemically identical to their full counterparts, making this process complicated. Enter mass photometry, a new bioanalytical technique that can efficiently characterize AAVs and distinguish between full and empty AAVs.

This webinar explores how mass photometry can circumvent challenges associated with AAVs, helping to accelerate therapeutic development and manufacturing.

Attend this webinar to: 

  • Discover how mass photometry is currently being used in industry
  • Learn how mass photometry can accurately measure empty/full AAV capsid ratios
  • Explore how to integrate mass photometry in a GMP-regulated environment
Speaker
A picture of Dr. Matt Ranaghan
Dr. Matt Ranaghan
Senior Applications Scientist
Refeyn
Brought to you by
Register for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar